Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.8%. By the end of trading, Teva Pharmaceutical Industries rose $1.13 (2.4%) to $49.29 on average volume. Throughout the day, 8,678,145 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6,348,300 shares. The stock ranged in a price between $48.02-$49.40 after having opened the day at $48.32 as compared to the previous trading day's close of $48.16. Other companies within the Health Care sector that increased today were: Aoxing Pharmaceutical Company ( AXN), up 18.9%, Aerie Pharmaceuticals ( AERI), up 14.8%, Pernix Therapeutics Holdings ( PTX), up 14.2% and Biostar Pharmaceuticals ( BSPM), up 13.9%.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $45.8 billion and is part of the drugs industry. Shares are up 20.2% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, InspireMD ( NSPR), down 14.3%, BioScrip ( BIOS), down 12.3%, Catamaran ( CTRX), down 10.9% and Questcor Pharmaceuticals ( QCOR), down 9.1% , were all laggards within the health care sector with Incyte ( INCY) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon